Annexon (ANNX) vs MannKind (MNKD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Annexon (ANNX) has outperformed MannKind (MNKD) over the past year, gaining 27.0% versus a loss of 37.1%. Over five years, MNKD leads with a -32.8% price change compared with -81.8% for ANNX. MannKind is the larger company by market cap ($1.06 billion vs $765.9 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | MNKD |
|---|---|---|
| Share price | $4.04 | $3.29 |
| Market cap | $765.90M | $1.06B |
| 1-day change | +1.00% | -3.80% |
| YTD return | -20.32% | -39.68% |
| 1-year return | +26.98% | -37.13% |
| 5-year return | -81.82% | -32.81% |
| Forward P/E | — | 25.80 |
| EPS (TTM) | $-1.13 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.18 | $6.51 |
| 52-week low | $2.54 | $2.23 |
| Distance from 52-week high | -43.73% | -49.46% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +281.93% | +138.30% |
| Average volume | 3.08M | 4.50M |
| Shares outstanding | 189.58M | 321.54M |
| Employees | 92 | 591 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANNX has outperformed MNKD by 64.1 percentage points over the past year.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About MannKind
MNKD stock →MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 591 employees
ANNX vs MNKD FAQ
Which is bigger, Annexon or MannKind?
MannKind (MNKD) is larger, with a market capitalization of $1.06B compared with $765.90M for Annexon (ANNX).
Which stock has performed better over the past year, ANNX or MNKD?
ANNX returned +26.98% over the past 12 months, compared with -37.13% for MNKD (price return, excluding dividends). Past performance does not predict future results.
Are Annexon and MannKind in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.